Biomarin Pharmaceutical Inc Asset Resilience Ratio
Biomarin Pharmaceutical Inc asset resilience ratio. Biomarin Pharmaceutical Inc (BMRN) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BMRN defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Biomarin Pharmaceutical Inc (1999–2025)
Asset resilience ratio of Biomarin Pharmaceutical Inc from 1999 to 2025. This chart shows how Biomarin Pharmaceutical Inc's Asset Resilience Ratio has changed over time. Read BMRN total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Biomarin Pharmaceutical Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BMRN total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Biomarin Pharmaceutical Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Biomarin Pharmaceutical Inc Industry Peers by Asset Resilience Ratio
Compare Biomarin Pharmaceutical Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 18.85% |
Biomarin Pharmaceutical Inc Asset Resilience Ratio by Year (1999–2025)
Biomarin Pharmaceutical Inc asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Biomarin Pharmaceutical Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.28% | $248.93 Million | $7.59 Billion | +0.49pp |
| 2024-12-31 | 2.79% | $194.86 Million | $6.99 Billion | -1.87pp |
| 2023-12-31 | 4.66% | $318.68 Million | $6.84 Billion | -4.24pp |
| 2022-12-31 | 8.89% | $567.01 Million | $6.38 Billion | +1.79pp |
| 2021-12-31 | 7.11% | $426.60 Million | $6.00 Billion | -0.01pp |
| 2020-12-31 | 7.12% | $416.23 Million | $5.85 Billion | +0.37pp |
| 2019-12-31 | 6.75% | $316.36 Million | $4.69 Billion | -6.59pp |
| 2018-12-31 | 13.33% | $590.33 Million | $4.43 Billion | -3.89pp |
| 2017-12-31 | 17.22% | $797.94 Million | $4.63 Billion | +7.74pp |
| 2016-12-31 | 9.48% | $381.35 Million | $4.02 Billion | +4.23pp |
| 2015-12-31 | 5.24% | $195.58 Million | $3.73 Billion | +2.45pp |
| 2014-12-31 | 2.80% | $69.71 Million | $2.49 Billion | -6.82pp |
| 2013-12-31 | 9.62% | $215.94 Million | $2.24 Billion | -7.61pp |
| 2012-12-31 | 17.23% | $270.21 Million | $1.57 Billion | +5.83pp |
| 2011-12-31 | 11.40% | $148.82 Million | $1.31 Billion | -3.34pp |
| 2010-12-31 | 14.73% | $186.03 Million | $1.26 Billion | +0.18pp |
| 2009-12-31 | 14.56% | $133.51 Million | $917.16 Million | -22.60pp |
| 2008-12-31 | 37.16% | $336.89 Million | $906.70 Million | -6.66pp |
| 2007-12-31 | 43.82% | $357.25 Million | $815.28 Million | +0.73pp |
| 2006-12-31 | 43.09% | $199.69 Million | $463.44 Million | +38.12pp |
| 2005-12-31 | 4.97% | $9.70 Million | $195.30 Million | -10.37pp |
| 2004-12-31 | 15.34% | $35.73 Million | $232.97 Million | -17.80pp |
| 2003-12-31 | 33.14% | $84.95 Million | $256.34 Million | -3.33pp |
| 2002-12-31 | 36.47% | $40.34 Million | $110.62 Million | -32.54pp |
| 2001-12-31 | 69.01% | $118.57 Million | $171.81 Million | +38.24pp |
| 2000-12-31 | 30.77% | $23.67 Million | $76.93 Million | -7.45pp |
| 1999-12-31 | 38.22% | $39.57 Million | $103.55 Million | -- |
About Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV t… Read more